Bionano Genomics Inc. (NASDAQ: BNGO) is -50.92% lower on its value in year-to-date trading and has touched a low of $0.25 and a high of $4.70 in the current 52-week trading range. The BNGO stock was last observed hovering at around $0.62 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $1.50 for the next 12 months. It is also 69.5% off the consensus price target high of $2.00 offered by 3 analysts, but current levels are 46.96% higher than the price target low of $1.15 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $0.61, the stock is -15.65% and -5.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.52 million and changing -1.84% at the moment leaves the stock -17.33% off its SMA200. BNGO registered -59.15% loss for a year compared to 6-month loss of -44.17%. The firm has a 50-day simple moving average (SMA 50) of $0.7171 and a 200-day simple moving average (SMA200) of $0.5814.
The stock witnessed a -22.96% gain in the last 1 month and extending the period to 3 months gives it a 23.57%, and is -0.93% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.03% over the week and 8.32% over the month.
Bionano Genomics Inc. (BNGO) has around 97 employees, a market worth around $85.60M and $8.40M in sales. Distance from 52-week low is 143.44% and -87.05% from its 52-week high. The company has generated returns on investments over the last 12 months (-114.90%).
Bionano Genomics Inc. (BNGO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Bionano Genomics Inc. (BNGO) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Bionano Genomics Inc. quarterly earnings per share for the current quarter are estimated at -$0.05 with sales reaching $2.12M over the same period.The EPS is expected to shrink by -8.20% this year, but quarterly earnings will post -21.00% year-over-year. Quarterly sales are estimated to shrink -36.00% in year-over-year returns.
Bionano Genomics Inc. (BNGO) Top Institutional Holders
21 institutions hold shares in Bionano Genomics Inc. (BNGO), with 14.42M shares held by insiders accounting for 10.41% while institutional investors hold 12.56% of the company’s shares. The shares outstanding are 138.48M, and float is at 136.15M with Short Float at 3.17%. Institutions hold 11.26% of the Float.
The top institutional shareholder in the company is Sio Capital Management, LLC with over 1.55 million shares valued at $0.79 million. The investor’s holdings represent 1.12% of the BNGO Shares outstanding. As of Jun 29, 2020, the second largest holder is Bank Julius Baer & Co. Ltd, Zurich with 0.75 million shares valued at $0.38 million to account for 0.54% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.35 million shares representing 0.26% and valued at over $0.18 million, while Geode Capital Management, LLC holds 0.23% of the shares totaling 0.32 million with a market value of $0.16 million.
Bionano Genomics Inc. (BNGO) Insider Activity
A total of 1 insider transactions have happened at Bionano Genomics Inc. (BNGO) in the last six months, with sales accounting for 0 and purchases happening 1 times.